2019

San Diego, CA

 

Day One
Wednesday March 28th, 2018

Day Two
Thursday March 29th, 2018

09.00
Chair’s Opening Remarks

Identifying Key Manufacturing Considerations for Efficient Large Scale Treatments

09.10
Stimulation of NK cells with the mbIL21 Platform: Manufacturing, Therapeutic, and Logistical Benefits

Synopsis

  • Platform for efficient and robust expansion
  • High anti-tumor activity, demonstrated clinically
  • Retention of active phenotype post-cryopreservation increases options for administration and distribution 
  • Continued innovation on the CytoSen platform can create new paradigm for delivering NK cell therapeutics

09.40
Process Development and Scale Up for NK Cell by Using Bioreactor

  • Sang Hoon Paik General Manager, Head of Process Unit, Cell Therapy Research Center, Green Cross LabCell

Synopsis

  • Identify the process of development for NK cell culture
  • Outline the use of a Bioreactor in the scale up of NK cell cultures

10.10
NK Cell Expansion and Activation through Engineered Cytokines

  • Saul Kivimae Team Lead, In Vivo Pharmacology Function for Preclinical Drug Development and Target Validation , Nektar Therapeutics

Synopsis

  • Multiple cytokines have the effect of simultaneously stimulating innate and adaptive immune cells
  • IL-2 and IL-15 have powerful and differentiable effects on different subpopulations of both NK cells and T-cells essential for tumor surveillance and eradication, but engineering of these cytokines is essential to make their signaling pathways medically accessible
  • Protein engineering through polymer conjugation has allowed the development of novel cytokine drugs with differentiable effects on NK populations through modulation of both the IL-2 and IL-15 signaling pathways.
  • NKTR-255 is an engineered IL-15 agonist, a promising addition to Nektar’s immunoncology pipeline that includes NKTR-214, a CD122 biased agonist, and NKTR-262, a TLR agonist, among other programs

10.40
Expansion of NK Cells Under Animal Component-free, Chemically Defined Condition

  • Jessie Ni Chief Scientific Officer , Irvine Scientific

Synopsis

  •  Review of NK cell cultures and potential challenges for scale up
  •  Development of NK Cell CDM using Rational by DesignTM approach
  •  Quality NK cell cultures under the ACF, CD condition

 

10.50
Morning Refreshments

Clinical Approaches to Create An Easily Accessible Off-The-Shelf Therapy

11.50
Development of FT516: Cornerstone Approach for Off-the-Shelf NK Cell Cancer Immunotherapy

  • Bob Valamehr Vice President, Cancer Immunotherapy and Reprogramming Biology, Fate Therapeutics

Synopsis

  • Master iPSC bank used as a renewable and consistent source for the manufacturing of engineered NK cells
  • FT516 is an NK cell product genetically edited to have augmented ADCC activity through modified CD16 transgene
  • FT516 displays enhanced cellular cytotoxicity as a monotherapy and when combined with therapeutic monoclonal antibodies
  • IND filing of FT516 is anticipated in 2018 and clinical trials to follow shortly

12.20
Allogeneic Natural Killer cell activity in cancer immunotherapy is enhanced by monoclonal antibodies

  • Wilfred Germeraad Chief Scientific Officer, Chief Operating Officer & Co-Founder, Cimaas

Synopsis

  • CiMaas is developing a GMP production system to generate NK cells
  • Such NK cells are fully functional in tumor cell kill assays
  • Monoclonal antbodies enhance NK cell activation and killing capacity.

12.50
The Natural Killer Cell as a Foundation to Next Generation Cancer Immunotherapies

  • David Pyrce SVP Innovation & Chief Commercial Officer , NantKwest, Inc.

Synopsis

  • Understand the need for an off-the-shelf, ready-to-use therapy that can deliver across both haematological and solid tumor
  • Outline the R&D and clinical path necessary to bring the next generation of NK cell-based immunotherapies to market and establish NK cell therapies as a key foundation to improved, more durable response rate and patient outcomes
  • Information on the NANT Cancer Vaccine Protocol that offers the potential as best-in-class novel combination therapy that synergistically harnesses both the innate and adaptive immune system

13.20
Lunch & Networking

Clinical Trial Case Studies

14.20
Priming Human NK cells to Kill NK-Resistant Tumors in The Absence of IL-2

  • Mark Lowdell Professor, Cell and Tissue Therapy , University College London

Synopsis

  • The biology of tumor-mediated priming of NK cells
  • Results of clinical trials in acute myeloid leukaemia
  • Pre-clinical data supporting the first trial of in vivo priming in metastatic ovarian cancer

14.50
oNKord® – Next generation products – From proven safety to established efficacy

  • Jan Spanholtz Chief Scientific Officer and Research and Development Manager, Glycostem Therapeutics

Synopsis

  • Discuss the development of Glycostem’s allogeneic cellular immunotherapy
  • Glycostem Therapeutics have a patented industrial applicable production platform technology that enables the generation of a multitude of products including: expanded stem cells, NK cells, dendritic cells and genetic modified versions of those
  • Identify the universal allogeneic treatment principle; the unrestricted use of immune cells in various types of cancer which is enabled by unlimited source of cord blood stem cells
  • New production improvements, logistic solutions for product availability and next clinical trials will be discussed

15.20
Potent Ex Vivo Expanded, Human CD34+ Cord Blood-derived Natural Killer Cells for Cancer Immunotherapy

Synopsis

  • Clinical studies suggest that adoptive transfer of allogeneic natural killer (NK) cells represent a promising treatment for patients with hematological malignancies and solid tumors
  • Celularity has established a cultivation process to generate human NK cells from umbilical cord blood (UCB) CD34+ cells with substantial cytolytic activity against several human tumor cell lines, primary AML and primary MM cells
  • Phase 1, multicenter, open-label, dose-escalating safety studies of PNK-007 infusion with subcutaneous recombinant human IL-2 in adults with AML and MM will be discussed

15.50
Afternoon Refreshments

Explore Clinical Advantages of Combinational Therapies

16.20
Panel Discussion: The Future Potential of NK cells In Combination Therapies

  • Sandip Patel Assistant Professor,, Medical Oncology/Hematology, UC San Diego Moores Cancer Center
  • Raymond Urbanski Chief Medical Officer, GT Biopharma
  • Joachim Koch Professor of Biochemistry Goethe-University Frankfurt and Research Program Head, Affimed

Synopsis

  • Identify the optimal sequence of treatment for successful combination therapy and detail their development in animal studies
  • Explore the use of targeted antibodies and cytokines to work alongside NK cells to improve their role in persistence and anti-tumor effects
  • Understand the cross-talk between NK cells and T cells, analyzing how an inflammatory microenvironment can stimulate the rest of adaptive immunity to work in combination to increase efficacy
  • Understand ways to exploit the full potential of an immunotherapeutic approach, defining a rational combination approach to maximize efficacies

16.50
NK Cell-Induced Immunity by Tetravalent Bispecific Immuno-Engagers in Patients Suffering from Hematologic Malignancies

  • Joachim Koch Professor of Biochemistry Goethe-University Frankfurt and Research Program Head, Affimed

Synopsis

  • Strategic concepts and functional characterization showing activation of innate immunity by tetravalent bispecific immuno-engagers
  • Opportunities to develop next-generation tetravalent bispecific immuno-engagers with tailored PK profiles
  • Update on NK cell engagers mediating tumor targeting of NK cells in hematologic malignancies
  • Discussion of rational combinations of tetravalent bispecific immuno-engagers with cellular therapies and immuno-stimulatory agents

17.20
Chair’s Closing Remarks

End of Day 2